Cns Mechanisms of S1p Receptor Signaling in Multiple Seclerosis
Year: 2023
Type: article
Abstract: Sphingosine 1-phosphate (S1P) is a lysophospholipid whose biological actions are primarily mediated by a subfamily of G protein-coupled receptors (GPCRs) referred to as S1P1-5. S1P receptor small-molecule modulators now account for four FDA-approved medicines (fingolimod, siponimod, ponesimod, and ozanimod) for the treatment of multiple sclerosis (MS), where they are best characterized as immunomodulators of lymphocyte trafficking. However, all receptor subtypes show brain expression during development and/or during adult life, and an expanding range of experimental data support their involvement in normal and disease processes that likely underlie their efficacy in MS.
Source: IBRO Neuroscience Reports
Institution: Sanford Burnham Prebys Medical Discovery Institute
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $1,500
OpenAlex ID: W4388385959